Tag: Solid
Biologics to garner $120 billion worth sales revenue by 2027, predicts...
Biologics are poised to emerge as dominating molecule type in solid tumor indication, overtaking innovative small molecules in terms of sales revenue, according to GlobalData
Curadev Pharma gets FDA nod for phase-1 study of its cancer...
The company has received US-FDA's 'Study May Proceed' letter for its Investigational New Drug Application of CRD3874, an IV-Administered STING Agonist for the treatment of advanced/metastatic solid cancers